Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction

Cardiology in Review

Volumn 20, Issue 6, 2012, Pages 319-324

  Norris, Davena M ^a   Anderson, Joe R ^b  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

hydroxymethylglutaryl coenzyme A reductase inhibitors; percutaneous coronary intervention; periprocedural myocardial infarction; statins

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; CREATINE KINASE MB; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; META ANALYSIS (TOPIC); MYALGIA; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; RISK REDUCTION; SIDE EFFECT; STABLE ANGINA PECTORIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INTRAOPERATIVE COMPLICATIONS; MYOCARDIAL INFARCTION; PERIOPERATIVE CARE; RETROSPECTIVE STUDIES; TIME FACTORS; WORLD HEALTH;

EID: 84867573275     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31826db7ff     Document Type: Review

References (32)

1. Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J. 2005;26:2493-2519.
2. Giannitsis E, von Lippa I, Müller Bardorff M, et al. Troponin T elevation after successful directional atherectomy. Z Kardiol. 2001;90:401-407.
3. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefnition of Myocardial Infarction. Universal defnition of myocar-dial infarction. Eur Heart J. 2007;28:2525-2538.
4. Zhang F, Dong L, Ge J. Effect of statins pretreatment on periprocedural myo-cardial infarction in patients undergoing percutaneous coronary intervention: a meta-analysis. Ann Med. 2010;42:171-177.
5. Ioannidis J P, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatinine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1406-1411.
6. Lindsey JB, Marso S P, Pencina M, et al.; EVENT Registry Investigators. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. JACC Cardiovasc Interv. 2009;2:1074-1082.
7. Cavallini C, Savonitto S, Violini R, et al.; Italian 'Atherosclerosis, Thorombo-sis, and Vascular Biology' and 'Society for Invasive Cardiology-GISE' Investigators. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J. 2005;26:1494-1498.
8. Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention: identifcation of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable beneft of statin therapy. Circulation. 2002;106:1205-1210.
9. Levine GN, Bates ER, Blankenship JC, et al.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiog-raphy and Interventions. J Am Coll Cardiol. 2011;58:e44-122.
10. Steinhubl SR, Lauer MS, Mukherjee D P, et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarcations. J Am Coll Cardiol. 1998;32:1366-1370.
11. Di Sciascio G, Patti G, Pasceri V, et al.; ARMYDA-5 PRELOAD Investigators. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYo-cardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol. 2010;56:550-557.
12. Blankenship JC, Tasissa G, O'Shea JC, et al.; ESPRIT Investigators. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol. 2001;38:653-658.
13. Ellis SG, Brener SJ, Lincoff AM, et al. beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise. Circulation. 2001;104:2685-2688.
14. Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation. 2002;106:2180-2183.
15. Chan AW, Bhatt DL, Chew D P, et al. Early and sustained survival beneft associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002;105:691-696.
16. Ko DT, Wijeysundera HC, Yun L, et al. Effectiveness of preprocedural statin therapy on clinical outcomes for patients with stable coronary artery disease after percutaneous coronary interventions. Circ Cardiovasc Qual Outcomes. 2011;4:459-466.
17. Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004;25:1822-1828.
18. Yun KH, Jeong MH, Oh SK, et al. The benefcial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2009;137:246-251.
19. Yun KH, Oh SK, Rhee SJ, et al. 12-month follow-up results of high dose rosu-vastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2011;146:68-72.
20. Cay S, Cagirci G, Sen N, et al. Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin. Cardiovasc Drugs Ther. 2010;24:41-47.
21. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009;54:2157-2163.
22. Veselka J, Zemánek D, Hájek P, et al. Effect of two-day atorvastatin pretreat-ment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study. Am J Cardiol. 2009;104:630-633.
23. Kim JS, Kim J, Choi D, et al. Effcacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv. 2010;3:332-339.
24. Pasceri V, Patti G, Nusca A, et al. Randomization trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation. 2004;110:674-678.
25. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272-1278.
26. Yu XL, Zhang HJ, Ren SD, et al. Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury. Coron Artery Dis. 2011;22:87-91.
27. Di Sciascio G, Patti G, Pasceri V, et al. Effcacy of atorvastatin reload in patients with chronic statin therapy undergoing percutaneous coronary intervention. Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol. 2009;54:558-565.
28. Cannon C P, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
29. Sun Y, Qi G, Gao Y, et al. Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. Can J Cardiol. 2010;26:481-485.
30. Smith SC Jr, Benjamin EJ, Bonow RO, et al.; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458-2473.
31. Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose atorvastatin pre-treatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Am J Cardiol. 2011;108:1-7.
32. Winchester DE, Wen X, Xie L, Bavry AA. Evidence of preprocedural statin therapy: a meta-analysis of randomized trials. J Am Coll Cardiol. 2010;56:1099-1109.